Table 1.
Patient characteristics (n = 31)
| Characteristics | No. |
|---|---|
| Gender | |
| Male | 22 (71%) |
| Female | 9 (29%) |
| Performance status | |
| 0 | 17 (55%) |
| 1 | 12 (39%) |
| 2 | 2 (6%) |
| Child-Pugh classification | |
| A | 27 (87%) |
| B | 4 (13%) |
| MELD score | |
| 6–7 | 17 (55%) |
| 8–9 | 11 (35%) |
| 10 ≤ | 3 (10%) |
| Viral marker | |
| HBs-Ag (+), HCV-Ab (−) | 2 (6%) |
| HBs-Ag (−), HCV-Ab (+) | 18 (58%) |
| HBs-Ag (+), HCV-Ab (+) | 1 (3%) |
| HBs-Ag (−), HCV-Ab (−) | 10 (33%) |
| Co-morbidity | |
| Diabetes mellitus | 10 (33%) |
| Hypertension | 16 (52%) |
| Cardiovascular disease | 8 (26%) |
| Respiratory disease | 5 (16%) |
| Chronic renal failure | 2 (6%) |
| Brain disease | 2 (6%) |
| Tumor size, mm, median [range] | 45 [15–93] |
| Serum AFP level, ng/ml, median [range] | 7.3 [1.3–48,058.3] |
| Serum AFP-L3, %, median [range] | 3.1 [< 0.5–84.2] |
| Serum PIVKA-II level, mAU/ml, median [range] | 85 [10–19,937] |
| Stage (UICC 7th edition) | |
| I | 24 (77%) |
| II | 4 (14%) |
| III | 3 (9%) |
| Stage (BCLC) | |
| A | 13 (42%) |
| B | 1 (3%) |
| C | 17 (55%) |
Abbreviations: MELD = Model for end-stage liver disease, HBs-Ag = Hepatitis B surface antigen, HCV-Ab = Hepatitis C virus antibody, AFP = Alpha-fetoprotein, AFP-L3 = Lens culinaris agglutinin-reactive fraction of AFP, PIVKA-II = Protein induced by vitamin K, AU = Arbitrary unit, UICC = Union for International Cancer Control classification, BCLC = Barcelona Clinic Liver Classification